Abeona Therapeutics (ABEO) to Release Quarterly Earnings on Thursday

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 15th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.11. On average, analysts expect Abeona Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Abeona Therapeutics Price Performance

Shares of ABEO traded up $0.13 during mid-day trading on Monday, hitting $6.23. The company's stock had a trading volume of 1,190,156 shares, compared to its average volume of 604,079. The firm has a 50-day moving average price of $5.20 and a 200 day moving average price of $5.55. The stock has a market capitalization of $304.02 million, a price-to-earnings ratio of -2.32 and a beta of 1.68. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. Abeona Therapeutics has a fifty-two week low of $3.93 and a fifty-two week high of $7.32.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ABEO shares. HC Wainwright lifted their price objective on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday, April 30th. Stifel Nicolaus lowered their price objective on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday. StockNews.com cut shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday. Oppenheimer started coverage on shares of Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price objective on the stock. Finally, Alliance Global Partners reissued a "buy" rating on shares of Abeona Therapeutics in a research report on Thursday. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.50.

Insider Buying and Selling

In related news, CEO Vishwas Seshadri sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,355,322 shares in the company, valued at approximately $6,478,439.16. This trade represents a 1.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mark Alvino sold 8,000 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $5.68, for a total transaction of $45,440.00. Following the sale, the director now owns 92,435 shares of the company's stock, valued at approximately $525,030.80. This represents a 7.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Abeona Therapeutics

A hedge fund recently raised its stake in Abeona Therapeutics stock. Goldman Sachs Group Inc. increased its stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 49.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 200,450 shares of the biopharmaceutical company's stock after purchasing an additional 66,422 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.41% of Abeona Therapeutics worth $954,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 80.56% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.